Resurfacing an April 2026 forecast: Indian pharma seen growing 8–10% in Q4, with US pressure set to squeeze margins
Indian pharmaceutical and healthcare companies were expected, per an April 2026 outlook, to deliver 8–10% year-on-year revenue growth in Q4FY26. US generics price erosion, higher marketing and R&D spending, and semaglutide launch costs in India are likely to weigh on profitability.
The development
Indian pharmaceutical and healthcare companies are expected to report 8–10 per cent Y-o-Y revenue growth in Q4FY26, but US generics erosion, elevated marketing and R&D spending, and India semaglutide-launch costs are expected to weigh on margins.
The numbers
- Q4FY26
- 8–10 per cent year-on-year (Y-o-Y)
- around 9 per cent Y-o-Y
- about 5.4 per cent
- 10–10.4 per cent
Why it matters to operators and investors
Plan for stable Q4 revenue growth but tighten cost control as US generics erosion, higher promotion and R&D, and semaglutide launch spending pressure margins.
The counter-case
The 8–10% revenue-growth forecast may prove optimistic if US generic price deflation accelerates, regulatory delays disrupt launches, or currency moves reduce reported sales. Margin pressure could be worse than expected because higher R&D, field-force spending and semaglutide commercialization costs may arrive before meaningful revenue, while competition limits the ability to pass costs through.